Healthcare / BiotechnologyKOSDAQ
$12840.00
-150.00 (-1.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-148.1B · quality 55.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$981.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-36.1%
↓Gross Margin
28.7%
↓Debt/Equity
2.97
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.5%
FCF CAGR
—
FCF margin
-17.7%
FCF / Net income
2.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.27T · net income $-109.88B · FCF $-224.59B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1268.25B | $1268.25B | $1045.05B | $953.95B | $844.58B |
| Net Income | $-109.88B | $-109.88B | $-4.76B | $-8.43B | $-47.54B |
| EBITDA | $-32.12B | $-32.12B | $79.26B | $70.09B | $-17.91B |
| EPS | -1649.00 | -1649.00 | -161.55 | -161.55 | -780.06 |
| Gross Margin | 28.7% | 28.7% | 26.3% | 29.0% | 24.2% |
| Operating Margin | -3.8% | -3.8% | -5.7% | -1.0% | -5.6% |
| Net Margin | -8.7% | -8.7% | -0.5% | -0.9% | -5.6% |
| Balance Sheet | |||||
| Debt/Equity | 2.97 | 2.97 | 2.89 | 1.60 | 1.37 |
| Current Ratio | 0.88 | 0.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-224.59B | $-224.59B | $-148.05B | $-62.86B | $-149.50B |
| Returns | |||||
| ROE | -36.1% | -36.1% | -1.7% | -3.0% | -16.3% |
| Valuation | |||||
| EV/EBITDA | — | — | 16.92 | 19.42 | — |
| P/B | 2.81 | 2.81 | 2.62 | 3.46 | 2.79 |
| Growth & Yield | |||||
| Revenue Growth | 21.4% | 21.4% | 9.5% | 12.9% | — |
| EPS Growth | -920.7% | -920.7% | 0.0% | 79.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+23.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-161.55 → -1649.00
Residual
+23.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.